Author Affiliations: INSERM, UMRS 938 (Drs Dorothée and Aucouturier); UPMC Univ-Paris6 (Drs Dorothée and Aucouturier); CRICM, UPMC Univ Paris 6, Pitie-Salpetriere Hospital (Drs de Souza and Sarazin); Alzheimer Institute, Research and Resource Memory Centre, Centre de Reference de Demences Rares, Centre de reference maladie d’Alzheimer jeune, AP-HP, Pitie-Salpetriere Hospital (Drs de Souza and Sarazin), Paris, France.
The question raised by Tremolizzo and colleagues relates to their recent observation that treatments with acetylcholinesterase inhibitors could impact the circulating levels of anti–amyloid β (Aβ) antibodies.1 As a matter of fact, our observation of significant differences in anti-Aβ antibody levels between patients with typical Alzheimer disease (AD) and patients with posterior cortical atrophy with evidence of AD (PCA-AD)2 could have been influenced by external factors including treatments. However, this possibility may be ruled out for the following 2 main reasons.
Dorothée G, Cruz de Souza L, Sarazin M, Aucouturier P. Plasma Anti–Amyloid-β Autoantibodies in All Alzheimer Disease Types—Reply. Arch Neurol. 2012;69(11):1525-1527. doi:10.1001/archneurol.2012.2779